Versor Investments LP Cuts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Versor Investments LP trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 71.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,095 shares of the medical equipment provider's stock after selling 7,805 shares during the quarter. Versor Investments LP's holdings in Lantheus were worth $248,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of LNTH. Silverberg Bernstein Capital Management LLC grew its holdings in Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock worth $1,834,000 after purchasing an additional 100 shares during the last quarter. Moody National Bank Trust Division grew its holdings in Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock worth $1,203,000 after purchasing an additional 162 shares during the last quarter. Shaker Investments LLC OH grew its holdings in Lantheus by 0.7% in the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider's stock worth $1,740,000 after purchasing an additional 182 shares during the last quarter. NBC Securities Inc. grew its holdings in Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider's stock worth $53,000 after purchasing an additional 191 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 208 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LNTH. Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday. They issued a "buy" rating and a $175.00 price target on the stock. Truist Financial lowered their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Leerink Partners lifted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. B. Riley lifted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Finally, JMP Securities lowered their price objective on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Stock Performance

NASDAQ LNTH traded down $3.36 on Friday, reaching $101.98. 561,405 shares of the company's stock traded hands, compared to its average volume of 1,036,350. The firm has a market cap of $7.07 billion, a price-to-earnings ratio of 15.57 and a beta of 0.50. The stock has a 50 day moving average price of $102.61 and a 200-day moving average price of $81.43. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company's revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.40 earnings per share. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at $4,990,171.89. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Gerard Ber sold 15,500 shares of the business's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company's stock, valued at $2,047,402.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the sale, the chief accounting officer now directly owns 62,557 shares of the company's stock, valued at approximately $4,990,171.89. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,193 shares of company stock worth $3,949,202. Company insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.